skacorica said:
Yes and no...for the purpose of these boards: it is not a muscle relaxant. Guaifenesin carbamate is used as a muscle relaxant because it is LONGER LASTING, however in the dosages with ephedrine even IT would have negligible effect. If you look it up, the dosages for muscle relaxant are not less than 1600mg of the carbamate.
I don't know as much about biochemistry as you but I remember that propanediol's (the form in Vaspro) are rapidly metabolized, thus there is no stacking effect between the dosages...but Ill modify the original to fit
dosage used of guaifenesin carbamate are 500mg, the equivalent of 400mg of guaifenesin. (a 1500mg dosage over the day- in three doses). A longer half life in this case is due to a slower release. 200mg is more than sufficient to have muscle relaxant effects. Probably not as strong as 500mg of guaifenesin carbamate- however still muscle relaxant effects.
half life of guaifenesin is 1hr (since most people take 45min to just prior to workout this is an issue)
some other interesting studies
J Altern Complement Med. 2004 Dec;10(6):967-9. Related Articles, Links
Ephedrine- and guaifenesin-induced nephrolithiasis.
Bennett S, Hoffman N, Monga M.
Department of Urologic Surgery, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455, USA.
OBJECTIVES: Ephedrine and guaifenesin are herbal supplements that have experienced increased use over the past decade. Ephedrine has been used as a stimulant and weight-loss product, guaifenesin as an expectorant and cough suppressant; both are found in combination in many antitussives and expectorants. This paper reviews the reported cases of ephedrine- and guaifenesin-induced nephrolithiasis, as well as the diagnostic techniques and treatments that have been successfully used for these stones. DESIGN: A systematic review of the literature pertaining to nephrolithiasis and the compounds ephedrine and guaifenesin was conducted. RESULTS: Ephedrine and guaifenesin use results in over 35% of urinary stones that are related to pharmaceutical metabolites, and collectively are present in 0.1% of all urinary stones. These calculi are radiolucent, requiring the use of computerized tomography (CT scan) for diagnosis. Alkalinization therapy offers an alternative to surgical intervention and may have a role in prevention of recurrence. CONCLUSIONS: Ephedrine and guaifenesin have been shown to cause nephrolithiasis in cases of abuse when taken individually or in combination. It is important for the clinician to be aware of the potential for these compounds to cause nephrolithiasis.